RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). Article

Gilbert, Mark R, Dignam, James, Won, Minhee et al. (2013). RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). . JOURNAL OF CLINICAL ONCOLOGY, 31(18_suppl), 1-1. 10.1200/jco.2013.31.18_suppl.1

cited authors

  • Gilbert, Mark R; Dignam, James; Won, Minhee; Blumenthal, Deborah T; Vogelbaum, Michael A; Aldape, Kenneth D; Colman, Howard; Chakravarti, Arnab; Jeraj, Robert; Armstrong, Terri S; Wefel, Jeffrey Scott; Brown, Paul D; Jaeckle, Kurt A; Schiff, David; Atkins, James Norman; Brachman, David; Werner-Wasik, Maria; Komaki, Ritsuko; Sulman, Erik P; Mehta, Minesh P

authors

publication date

  • June 20, 2013

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Genetics
  • Neurosciences
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 1

end page

  • 1

volume

  • 31

issue

  • 18_suppl